Physician profile
Sanjiv Modi
NPI 1396730909
$77,268.22
in general payments reported to CMS, 2019-2025
62 companies · $623 in 2025
The $623 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16K · 2020: $43K · 2021: $2,031 · 2022: $16K · 2023: $509 · 2025: $623.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,131.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,131.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $53,777.59 | 2020-2025 | Enhertu |
| Janssen Pharmaceuticals, INC | $14,529.36 | 2019-2023 | Xarelto |
| Jazz Pharmaceuticals INC. | $2,531.75 | 2020-2025 | |
| Janssen Biotech, INC. | $640.02 | 2019-2025 | Rybrevant, Carvykti, Darzalex |
| Beigene, Ltd. | $450.00 | 2020 | |
| Merck Sharp & Dohme LLC | $424.71 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $387.17 | 2019-2023 | Opdivo |
| Astrazeneca Pharmaceuticals Lp | $322.20 | 2019-2025 | Datroway, Imfinzi |
| Genentech USA, INC. | $305.44 | 2019-2023 | Tecentriq |
| Pfizer INC. | $301.56 | 2019-2025 | |
| Lilly USA, LLC | $267.12 | 2019-2023 | Verzenio, Retevmo |
| Novartis Pharmaceuticals Corporation | $244.62 | 2019-2022 | |
| Karyopharm Therapeutics INC. | $216.27 | 2020-2021 | |
| Pharmacyclics LLC, An Abbvie Company | $215.15 | 2019-2023 | Imbruvica |
| Amgen INC. | $186.78 | 2019-2023 | Prolia |
Show all 62 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sanjiv Modi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.